Replies to post #163365 on Biotech Values

[biomaven0]

>long-lasting metabolite

Could be good (because it might make the drug QD instead of BID) but may also complicate the development and approval strategy. If this metabolite is not similarly present in their animal tox testing, then they might have to redo some of that testing as if the metabolite was a new drug.

The discussion was on the INCY thread here:

http://www.siliconinvestor.com/readmsg.aspx?msgid=28949413

Peter